{"analyses":[{"ciLowerLimit":".81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":".84","paramType":"Hazard Ratio (HR)","paramValue":".98","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.9","upperLimit":"92.3","value":"91.2"},{"groupId":"OG001","lowerLimit":"89.6","upperLimit":"92.1","value":"90.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2426"},{"groupId":"OG001","value":"2425"}],"units":"Participants"}],"description":"Duration of time from randomization to the first indication of the following events: invasive breast recurrence at local, regional or distant sites; a new invasive cancer in the contralateral breast (second non-breast malignancies are ignored). In the absence of an event, BCFI was censored at the date of last follow-up visit or date of death without prior breast cancer event.","dispersionType":"95% Confidence Interval","groups":[{"description":"Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)\n\nLetrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously","id":"OG000","title":"Arm A: Continuous Letrozole"},{"description":"Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\\> 36 mo) plus 1 x 12 mo in yr 5 -\\> 48 months\n\nLetrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\\> 36 mo) plus 1 x 12 mo in yr 5 -\\> 48 months","id":"OG001","title":"Arm B: Intermittent Letrozole"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"5-year estimates, reported at a median follow-up of 60 months","title":"Breast Cancer-free Interval","type":"SECONDARY","unitOfMeasure":"percentage of patients"}